Grant H. Skrepnek, Ph.D., R.Ph.

Professor

Pharmacy Clinical & Admin Sci

Phone (405) 271-6878 x47105

Fax (4050 271-6430

Office CPB 214

Email grant-skrepnek@ouhsc.edu


Summary

I concentrate on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, I focus on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. I am engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.



Research

Dr. Skrepnek concentrates on health economics, policy, and outcomes research involving large-scale database investigations, decision analyses, clinical trials, and survey research. From a clinical stance, Dr. Skrepnek focuses on studying cost, quality, and access to care across various healthcare settings concerning oncology, cardiopulmonary disease, rare conditions, and comorbidities. He is engaged in advancing the methodological approaches used within assessments of health technology, including the development of novel statistical procedures to evaluate health and economic data.




Publications & Presentations

    101. Armstrong E P, Skrepnek G H, Haim Erder M. Cost-utility comparison of escitalopram and sertraline in the treatment of major depressive disorder. Current medical research and opinion. 2007; 23 : 251-8

    102. Ventura D, Armstrong E P, Skrepnek G H, Haim Erder M. Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial. Current medical research and opinion. 2007; 23 : 245-50

    103. Elliott W J, Plauschinat C A, Skrepnek G H, Gause D. Persistence, adherence, and risk of discontinuation associated with commonly prescribed antihypertensive drug monotherapies. Journal of the American Board of Family Medicine : JABFM. 2007; 20 : 72-80

    104. Skrepnek G H. The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis. PharmacoEconomics. 2007; 25 : 649-64

    105. Abarca J, Malone D C, Skrepnek G H, Rehfeld R A, Murphy J E, Grizzle A J, Armstrong E P, Woosley R L. Community pharmacy managers' perception of computerized drug-drug interaction alerts. Journal of the American Pharmacists Association : JAPhA. 2006; 46 : 148-53




Grants

1 2 3 4 >>
    1. [Cooperative Agreement] Oklahoma State Department of Health, A Strategic Approach to Advancing Health Equity for Priority Populations with or at Risk for Diabetes – 2023 (DP-23-0020, FAIN #NU58DP007376, CFDA #93.988 (Cooperative Agreements for State-Based Diabetes Control Programs and Evaluation of Surveillance Systems). . CDC. Start Date: 2023. End Date: 2024.

    2. [Cooperative Agreement] Oklahoma State Department of Health, Chronic Disease Prevention Program: The National Cardiovascular Health Program (DP-23-0004, FAIN #NU58DP007471, CFDA #93.426 - The National Cardiovascular Health Program, CDV/Heart. CDC. Start Date: 2023. End Date: 2024.

    3. HIV Adherence Services. Start Date: 2022. End Date: 2023.

    4. Patterns of Care, Outcomes, and Barriers to Treatment Success or Vaccination Associated with Adult Community-Acquired Pneumonia in Medicaid. Misc Non-Federal. Start Date: 2021. End Date: 2022.

    5. [Service Agreement] Opioid Use Under Oklahoma Senate Bill 848.. Non-federal. Start Date: 2020. End Date: 2020.

1 2 3 4 >>



Awards and Honors


no results

Education


no results